Holen Sie sich die Stockscreener-App
1.36
0.00%
0.00
Schlusskurs vom Vortag:
$1.36
Offen:
$1.39
24-Stunden-Volumen:
551.85K
Relative Volume:
0.49
Marktkapitalisierung:
$148.93M
Einnahmen:
$78.09M
Nettoeinkommen (Verlust:
$-31.99M
KGV:
-3.7466
EPS:
-0.363
Netto-Cashflow:
$-22.12M
1W Leistung:
+3.03%
1M Leistung:
-7.80%
6M Leistung:
-25.27%
1J Leistung:
-46.03%
1-Tages-Spanne:
$1.345
$1.405
1-Wochen-Bereich:
$1.3091
$1.41
52-Wochen-Spanne:
$0.9583
$2.98
Codexis Inc Stock (CDXS) Company Profile
Firmenname
Codexis Inc
Sektor
Branche
Telefon
650-421-8100
Adresse
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.36 | 144.55M | 78.09M | -31.99M | -22.12M | -0.363 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-19 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-29 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-07 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-08-07 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2021-04-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-01 | Eingeleitet | Stifel | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-10 | Eingeleitet | The Benchmark Company | Buy |
| 2019-01-17 | Hochstufung | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | Eingeleitet | Stephens | Overweight |
| 2017-10-13 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-31 | Eingeleitet | Jefferies | Buy |
| 2017-01-26 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Codexis Inc Aktie (CDXS) Neueste Nachrichten
Codexis partners with siRNA innovator on enzyme synthesis By Investing.com - Investing.com Canada
Codexis Enters into an Agreement with Pioneering siRNA Drug - GlobeNewswire
Codexis, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (CDXS) - Traders Union
Codexis at Cantor conference: enzymatic RNA manufacturing gains ground By Investing.com - Investing.com Canada
Codexis (CDXS) Q2 2026 Earnings: Loss Narrower Than Expected, Shares Decline 2.03%Revenue Per Share - vinanet.vn
Codexis (CDXS) Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers a 7.67% EPS SurpriseEarnings Call Transcript - dars.gov.et
Codexis (CDXS) Slides 3.61% to $1.60: Key Support Levels Under ScrutinyBollinger Expansion - vinanet.vn
Codexis to Participate in Cantor Global Healthcare Conference 2026 - GlobeNewswire
Codexis (CDXS) Financial Results: The Available Earnings Metric Delivers a Beat in the Latest Reading; Session Move - vinanet.vn
Codexis (CDXS) Q2 2026 Earnings Call Transcript - The Globe and Mail
CDXS Maintained by Piper Sandler -- Price Target Lowered to $8.0 - GuruFocus
CDXS Looks 39.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
CDXS Looks 39.1% Undervalued on GF Value™ - GuruFocus
Codexis (NASDAQ:CDXS) Cut to "Sell" at Wall Street Zen - MarketBeat
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares - Stock Titan
CDXS Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 8% Stock SurgeSpecial Dividend Alert - dars.gov.et
Codexis Reports Second Quarter 2026 Financial Results - The Manila Times
Codexis earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Codexis, Inc. Stock 12‑Month Price Target Cut to $6.5, Implies 339% Upside - TradingView
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... - finance.yahoo.com
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocataly - GuruFocus
Codexis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
CDXS Looks 40.1% Undervalued on GF Value™ Amidst Challenging Fun - GuruFocus
Codexis narrows Q2 loss, raises $25M to fund GMP expansion - scanx.trade
Codexis Affirms FY26 Sales Guidance Range Amid Stable Outlook - scanx.trade
Transcript : Codexis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Codexis (NASDAQ:CDXS) Issues Earnings Results - MarketBeat
Codexis Q2 Earnings Call Highlights - MarketBeat
CDXS: Q2 2026 saw revenue of $14.9M, margin gains, new financing, and major ECO Synthesis advances - tradingview.com
Earnings call transcript: Codexis beats Q2 2026 estimates as shares rise after hours - Investing.com
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
How Did Codexis Inc (CDXS) Perform in Q2? EPS at -0.14, Revenue Beats Estimates; GF Score: 49/100 - GuruFocus
Codexis, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CODEXIS ($CDXS) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Codexis: Q2 Earnings Snapshot - marketscreener.com
Codexis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Codexis Q1 2026 Earnings: EPS Beats Estimates by 28.26% as Stock Slips 1.33%Earnings Weakness Phase - dars.gov.et
Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Codexis, Inc. expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Price Performance - Yahoo! Finance Canada
Codexis, Inc. Revenue Breakdown – NASDAQ:CDXS - TradingView
Codexis (CDXS) Projected to Release Earnings on Tuesday - MarketBeat
Codexis Inc (CDXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Codexis appoints David Butler to strategic advisory board - Investing.com
Codexis appoints David Butler to strategic advisory board By Investing.com - Investing.com Australia
Codexis Appoints David Butler, PhD, to Strategic Advisory Board - The Manila Times
Press Release: Codexis Appoints David Butler, PhD, to Strategic Advisory Board - Moomoo
CDXS Q1 2026 Earnings: Narrower-Than-Expected Loss of -$0.10 per Share, Yet Stock Declines 5.41%Profit Warning Alert - dars.gov.et
CDXS Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Surprise BeatGuidance Downgrade Alert - dars.gov.et
Codexis, Inc. (CDXS) investors report 7.3% stake in 7.85M shares - Stock Titan
Finanzdaten der Codexis Inc-Aktie (CDXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Codexis Inc-Aktie (CDXS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lutz Stefan | Chief Scientific Officer |
Feb 24 '26 |
Sale |
1.13 |
5,862 |
6,641 |
130,421 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):